Therapeutic aspects of autoimmune diseases of the skin

  • Michael Sticherling


The skin represents the largest and at the same time most exposed organ of the human body. Apart from infectious, inflammatory, and neoplastic conditions it can be involved by autoimmune reactions as well. These may result in distinct clinical entities where the skin is the main or only target as found among autoimmune bullous skin diseases. In contrast, skin symptoms are seen as one of several disease manifestations in the context of collagenoses which represent multiorgan diseases. A third group of skin manifestations presents with uncharacteristic symptoms which simply reflect autoimmune diseases of internal organs (Table 1).


Allergy Clin Immunol Fumaric Acid Bullous Pemphigoid Alopecia Areata Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahmed AR (2001) Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45: 825–835PubMedCrossRefGoogle Scholar
  2. Altmeyer P, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P (1994) Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30:977–981PubMedCrossRefGoogle Scholar
  3. Ameen M, Exarchou V, Chu AC (2001) Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 145: 476–479PubMedCrossRefGoogle Scholar
  4. Anstey A (1996) Management of immunobullous disorders: the clinical significance of interindividual variation in azathioprine metabolism. Clin Exp Dermatol 21: 247–248PubMedCrossRefGoogle Scholar
  5. Becker L, Bastian B, Wesselmann U, Karl S, Hamm H, Brocker EB (1998) Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur J Dermatol 8: 551–553PubMedGoogle Scholar
  6. Bodemer C, Teillac D, Le Bourgeois M, Wechsler B, de Prost Y (1990) Efficacy of intravenous immun-globulins in sclerodermatomyositis. Br J Dermatol 123: 545–546PubMedCrossRefGoogle Scholar
  7. Bornhovd E, Burgdorf WH, Wollenberg A (2001) Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 45: 736–743PubMedCrossRefGoogle Scholar
  8. Bottomley WW, Goodfield MJ (1995) Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol 133: 655–656PubMedCrossRefGoogle Scholar
  9. Burt RK, Slavin S, Burns WH, Marmont AM (2002) Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 99: 768–784PubMedCrossRefGoogle Scholar
  10. Cronstein BN (1996) Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 39:1951–1960PubMedCrossRefGoogle Scholar
  11. Dalakas MC (1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22: 1479–1497PubMedCrossRefGoogle Scholar
  12. De Vita S, Ferraccioli GF, Di Poi E, Bartoli E, Bombardieri S (1996) High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. Clin Exp Rheumatol 14: S85–S92PubMedGoogle Scholar
  13. Dutz JP, Ho VC (1998) Immunosuppressive agents in dermatology: an update. Dermatol Clin 16: 235–251PubMedGoogle Scholar
  14. Edwards KR, Burke WA (1999) Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 41: 1049–1050PubMedCrossRefGoogle Scholar
  15. Ermis O, Alpsoy LC, Yilmaz E (2001) Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 145: 472–475PubMedCrossRefGoogle Scholar
  16. Fleischli ME, Rachel H, Valek BS, Pandya AG (1999) Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol 135: 57–61PubMedCrossRefGoogle Scholar
  17. Furst DE (1999) Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (Oxford) 38: 14–18CrossRefGoogle Scholar
  18. Gasparro FP (2000) Photodermatology: progress, problems and prospects. Eur J Dermatol 10: 250–254PubMedGoogle Scholar
  19. Gelfand Erwin W (2001) Antibody-directed therapy: past, present and future. J Allergy Clin Immunol 108: 111–116CrossRefGoogle Scholar
  20. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Ragi Eis S, Gennari C, Johnell 0, Johnston CC Jr, Lau EM, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, Khaltaev N (1999) Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10: 259–264PubMedCrossRefGoogle Scholar
  21. Georgala S, Katoulis AC, Hasapi V, Koumantaki-Mathioudaki E (1998) Thalidomide treatment for hypertrophic lupus erythematosus. Clin Exp Dermatol 23: 141PubMedCrossRefGoogle Scholar
  22. Giant TT, Mikecz K, Brennan F, Negroiu G, Bartlett R (1998) Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritis. J Rheumatol 25: 20–26Google Scholar
  23. Glied M, Rico MJ (1999) Treatment of autoimmune blistering diseases. Dermatol Clin 17: 431–440PubMedGoogle Scholar
  24. Isaacs JD (2001) From bench to bedside: discovering rules for antibody design, and improving serotherapy with monclonal antibodies. Rheumatology (Oxford) 40: 724–738CrossRefGoogle Scholar
  25. Jayne D (1999) Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens 8: 563–567PubMedCrossRefGoogle Scholar
  26. Jeffes EW 3rd, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al (1995) Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 104: 184–188CrossRefGoogle Scholar
  27. Jolles S, Hughes J, Whittaker S (1998) Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 134: 80–86PubMedCrossRefGoogle Scholar
  28. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D’Incan M, Plantin P, Bedane C, Young P, Bernard P, The Bullous Diseases French Study Group (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346: 321–327PubMedCrossRefGoogle Scholar
  29. Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46: 1–23PubMedCrossRefGoogle Scholar
  30. Kurtz ES, Bay ley SC, Arshad F, Lee AA, Przekop PA (1995) Leflunomide: an active antiinflammatory and antiproliferative agent in models of dermatologic disease. Inflamm Res 44: 187–188CrossRefGoogle Scholar
  31. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN (2000) Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 39: 218–222PubMedCrossRefGoogle Scholar
  32. Lamba S, Lebwohl M (2001) Combination therapy with vitamin D analogues. Br J Dermatol 144: 27–32PubMedGoogle Scholar
  33. Luger T (2001) Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 11: 343–347PubMedGoogle Scholar
  34. Mrowietz U (2001) Advances in systemic therapy for psoriasis. Clin Dermatol 26: 362–367CrossRefGoogle Scholar
  35. Mrowietz U, Christophers E, Altmeyer P (1999) Treamtent of severe psoriasis with fumaric acid esters scientific background and guidelines for therapeutic use. Br J Dermatol 141: 424–429PubMedCrossRefGoogle Scholar
  36. Nousari HG, Anhalt GJ (2000) Bullous pemphigoid treated with leflunomide. Arch Dermatol 136: 1204–1205PubMedCrossRefGoogle Scholar
  37. Ochsendorf FR, Runne U (1996) Chloroquine: consideration of maximum daily dose (3.5 mg/kg ideal body weigth) prevents retinopathy. Dermatology 192: 382–383PubMedCrossRefGoogle Scholar
  38. O’Donnell BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N, Barlow RJ, Winkelmann RK, Greaves MW (1998) Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 138: 101–106PubMedCrossRefGoogle Scholar
  39. Ordi-Ros J, Cortes F, Cucrull E, Mauri M, Bujan S, Vilardell M (2000) Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 27: 1429–1433PubMedGoogle Scholar
  40. Parnham MJ (1995) Leflunomide: a potential new disease modifying anti-rheumatic drug. Exp Opin Invest Drugs 4: 777–779CrossRefGoogle Scholar
  41. Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G (1996) Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 34: 244–252PubMedCrossRefGoogle Scholar
  42. Rabinovitch N, Gelfand EW, Leung DY (1999) The role of immunoglobulin therapy in allergic diseases. Allergy 54: 662–668PubMedCrossRefGoogle Scholar
  43. Richter HI, Krutmann J, Goerz G (1998) Extrakorporale Photopherese bei therapieresistentem disseminiert diskoidem Lupus erythematodes. Hautarzt 49: 487–491PubMedCrossRefGoogle Scholar
  44. Robert C, Kupper TS (1999) Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 341: 1817–1828PubMedCrossRefGoogle Scholar
  45. Roujeau JC (1999) Treatment of severe drug eruptions. J Dermatol 26: 718–722PubMedGoogle Scholar
  46. Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, Prudlo C, Pawelczyk B, Messmer EM, Schumann M, Sinkgraven R, Biichner L, Budinger L, Pfeiffer C, Sticherling M, Hertl M, Kaiser H-W, Meurer M, Zillikens D, Messer G (2002) Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol 138: 903–908PubMedCrossRefGoogle Scholar
  47. Sacher RA (2001) Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108: 139–146CrossRefGoogle Scholar
  48. Sadayama T, Miyagawa S, Shirai T (1999) Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol 26: 457–459Google Scholar
  49. Saeki Y, Oshima S, Kurimoto I, Miura H, Suemura M (2000) Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 9: 390–392PubMedCrossRefGoogle Scholar
  50. Sapadin AN, Fleischmajer R (2002) Treatment of scleroderma. Arch Dermatol 138: 99–105PubMedCrossRefGoogle Scholar
  51. Sauder DN (2000) Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 43: S6–S11PubMedCrossRefGoogle Scholar
  52. Sticherling M (2001) Chronic cutaneous lupus erythematosus. In: Hertl M (ed) Autoimmune disease of the skin: pathogenesis, diagnosis, management. Springer, Wien New York, pp 169–187Google Scholar
  53. Tan BB, Lear TJ, Gawkrodger DJ, English JS (1997) Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol 136: 351–355PubMedCrossRefGoogle Scholar
  54. Thivolet J, Nicolas JF, Kanitakis J, Lyonnet S, Chouvet B (1990) Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. Br J Dermatol 122: 405–409PubMedCrossRefGoogle Scholar
  55. Thoma-Uszynski S, Hertl M (2001) Novel therapeutic approaches in autoimmune skin disorders. In: Hertl M (ed) Autoimmune disease of the skin: pathogenesis, diagnosis, management. Springer, Wien New York, pp 337–364Google Scholar
  56. Warren KJ, Nopper AJ, Crosby DL (1998) Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus. J Am Acad Dermatol 39: 293–295PubMedCrossRefGoogle Scholar
  57. Werth VP (1993) Management and treatment with systemic glucocorticoids. Adv Dermatol 8: 81–101PubMedGoogle Scholar
  58. Wollina U, Looks A (1999) Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 13: 127–130PubMedCrossRefGoogle Scholar
  59. Wozel G (1996) Dapson: Pharmakologie, Wirkmechanismus und klinischer Einsatz. Thieme, Stuttgart.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Michael Sticherling
    • 1
  1. 1.Department of DermatologyUniversity of LeipzigLeipzigFederal Republic of Germany

Personalised recommendations